Neogenomics (NEO) Enterprise Value (2010 - 2026)

Neogenomics (NEO) has 17 years of Enterprise Value data on file, last reported at -$145.5 million in Q2 2026.

• Quarterly Enterprise Value rose 11.09% year-over-year to -$145.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$145.5 million (up 11.09% YoY) and the FY2025 annual result came in at -$159.6 million, up 58.74% from the prior year.
• Enterprise Value steadied at -$145.5 million in Q2 2026, from -$146.1 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$145.5 million in Q2 2026 to a low of -$481.4 million in Q1 2022.
• A 5-year average of -$342.1 million and a median of -$387.8 million in 2024 frame the typical range for Enterprise Value.
• Annual changes were most pronounced in 2024 — Enterprise Value climbed 3.59% — and 2026, when it jumped 59.19%.
• Tracing NEO's Enterprise Value over 5 years: stood at -$438.0 million in 2022, then gained by 5.2% to -$415.2 million in 2023, then increased by 6.83% to -$386.8 million in 2024, then surged by 58.74% to -$159.6 million in 2025, then advanced by 8.82% to -$145.5 million in 2026.
• The last three Enterprise Value figures came in at -$145.5 million (Q2 2026), -$146.1 million (Q1 2026), and -$159.6 million (Q4 2025), per Business Quant data.